Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739626 | 0.93 | NR1I3 (0.41) | GAAMAPTKDM4ENR1I3MEN1 | |
| SCHEMBL14739952 | 0.90 | KDM1A (0.40) | MAPTNR1I3LMNAMAPKAPK2POLB | |
| SCHEMBL14740051 | 0.90 | NR1I3 (0.43) | GAAKDM4ENR1I3KMT2APOLB | |
| SCHEMBL14740103 | 0.86 | NR1I3 (0.41) | KDM4ENR1I3KMT2ADPP4 | |
| SCHEMBL14739332 | 0.86 | MAPK13 (0.41) | GAAKDM4ENR1I3POLBALDH1A1 | |
| SCHEMBL14739599 | 0.85 | NR1I3 (0.41) | GAAKDM4ENR1I3POLBALDH1A1 | |
| SCHEMBL14739276 | 0.84 | NR1I3 (0.43) | GAAKDM4ENR1I3POLBALDH1A1 | |
| SCHEMBL14739888 | 0.84 | NR1I3 (0.40) | GAAMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL14739596 | 0.84 | MAPT (0.39) | GAAMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL14740120 | 0.84 | NR1I3 (0.43) | GAAKDM4ENR1I3MAPKAPK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | claimed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | GAA 1998/4885MAPT 4300/4885TP53 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.